Standard blood work like a complete blood count or metabolic panel will not reliably detect breast cancer. These routine tests weren’t designed to find cancer, and most people with early-stage breast cancer have completely normal blood results. There are specialized blood-based tests, including tumor markers and newer technologies, but none are currently recommended for screening or diagnosing breast cancer in people without symptoms.
What Routine Blood Tests Can and Can’t Tell You
A complete blood count measures your white blood cells, red blood cells, hemoglobin, and platelets. These values reflect your overall health but don’t point specifically to breast cancer. Your counts could be perfectly normal even with a tumor growing in your breast. The main exception is advanced disease: if breast cancer has spread to the bone marrow, it can disrupt blood cell production and cause abnormal counts, particularly anemia from low red blood cells. But by that point, cancer has already progressed well beyond its original site.
A basic metabolic panel, which checks things like calcium, liver enzymes, and kidney function, is similarly non-specific. Elevated calcium levels can sometimes signal that cancer has spread to the bones, since up to 30% of cancer patients develop high calcium at some point. In metastatic breast cancer specifically, high calcium most often results from bone metastases and tends to be mildly elevated, in the range of 10.5 to 11.9 mg/dL. Elevated liver enzymes can hint at cancer that has spread to the liver. But these changes only appear in advanced or metastatic disease, not in early breast cancer, and plenty of non-cancerous conditions cause the same abnormalities.
Tumor Markers for Breast Cancer
There are blood tests designed to detect proteins shed by breast cancer cells. The most common are CA 15-3, CA 27.29, and CEA. These markers measure a protein called MUC-1 that circulates in the blood when breast cancer is present, particularly when it has spread. Between 75% and 90% of patients with metastatic breast cancer will have elevated levels of these markers.
The problem is sensitivity in early disease. In patients without metastasis, CA 27.29 catches only about 6.4% of cases, CA 15-3 catches 5.5%, and CEA catches 4.5%. That means more than 9 out of 10 people with non-metastatic breast cancer would get a normal result. In metastatic disease, the numbers improve dramatically: CA 27.29 picks up roughly 86% of cases and CA 15-3 about 83%.
These markers also aren’t specific to cancer. Chronic hepatitis raises CA 15-3 levels in about 43% of cases. Liver cirrhosis, sarcoidosis, tuberculosis, and lupus can all cause false elevations. Because of this poor performance in early detection and the risk of misleading results, the American Society of Clinical Oncology explicitly recommends against using CA 15-3 or CA 27.29 for screening, diagnosis, or staging. Their main role is monitoring patients who already have a known diagnosis, particularly tracking whether treatment for metastatic disease is working.
Circulating Tumor DNA Tests
A newer category of blood tests looks for tiny fragments of tumor DNA floating in the bloodstream, often called a “liquid biopsy.” In advanced breast cancer, these tests have proven highly accurate. The plasmaMATCH trial found a 96% to 99% match between mutations detected in blood and those found in tumor tissue. This means a blood draw can reliably reveal what genetic mutations are driving the cancer, helping oncologists choose targeted treatments without needing a new tissue biopsy.
For early-stage disease, the picture is much less clear. Early tumors release very small amounts of DNA into the blood, making detection difficult. Current guidelines recommend circulating tumor DNA testing only for genotyping advanced disease, not for screening or early detection. The low abundance of tumor material in blood at early stages creates a real risk of false-negative results, where someone has cancer but the test misses it.
One intriguing avenue involves detecting tumor DNA in breast milk. Early research found that tumor-derived DNA fragments in breast milk mirrored those in the tumor itself, with higher sensitivity than standard blood testing. In a small study, these fragments were detectable up to 18 months before a clinical diagnosis in two participants. This is still very early-stage research with a small number of participants, but it suggests the bodily fluid being tested matters.
Circulating Tumor Cell Tests
Another approach counts and profiles whole cancer cells circulating in the bloodstream. One test evaluated in both case-control and prospective studies showed promising numbers: 100% specificity and 92% overall sensitivity when comparing breast cancer patients to healthy women. In a prospective study that included women with benign breast conditions, it maintained about 93% specificity and 95% sensitivity.
Performance varied by stage. For the earliest stage (stage 0, or ductal carcinoma in situ), sensitivity was around 70% to 88% depending on the study design. For stage I, it rose to roughly 89% to 96%. Stages II through IV reached 95% to 100%. These numbers look encouraging, but ASCO’s current guidelines still state that circulating tumor cell measurement should not be used to diagnose breast cancer or to influence treatment decisions. The gap between study results and clinical guidelines reflects the long validation process required before a test becomes part of standard care.
Why Imaging and Biopsy Remain the Standard
Breast cancer is still diagnosed through a combination of imaging (mammography, ultrasound, or MRI) followed by a tissue biopsy if something suspicious is found. A biopsy, where a small sample of tissue is removed and examined under a microscope, is the only way to definitively confirm breast cancer. No blood test has replaced this sequence.
The reason is straightforward: blood tests either lack the sensitivity to catch early cancers or lack the specificity to distinguish cancer from benign conditions. A mammogram can identify a suspicious mass when it’s a few millimeters in size. A blood test for tumor markers, by contrast, will miss the vast majority of early tumors. Even the most promising newer technologies haven’t yet demonstrated the consistent accuracy across large, diverse populations needed to justify replacing or supplementing standard screening.
What Abnormal Blood Work Might Actually Mean
If you had routine blood work done and something came back abnormal, the chances that it points to breast cancer are very low. Anemia has dozens of common causes, from iron deficiency to chronic disease. Elevated liver enzymes are frequently caused by medications, fatty liver disease, or alcohol. High calcium is often related to overactive parathyroid glands, not cancer.
That said, certain patterns in someone already diagnosed with breast cancer can be meaningful. Rising tumor markers during follow-up may indicate recurrence. New anemia, elevated calcium, or abnormal liver function tests in a breast cancer survivor could suggest the disease has spread to bone, liver, or bone marrow. In these contexts, blood work plays an important supporting role, even though it isn’t the tool that made the original diagnosis.
For people without a breast cancer diagnosis who are worried about detection, regular screening mammograms remain the most effective tool. Blood-based screening may eventually become part of that picture, but it isn’t there yet.